Liquormarkers als voorspellers van Alzheimer-dementie

An increasing number of people with mild cognitive impairment (MCI) visits a memory clinic to find out whether their symptoms indicate Alzheimer’s disease (AD). Markers in cerebrospinal fluid are increasingly used for the diagnosis of Alzheimer’s disease.

In the short term, CSF biomarkers are more accurate in ruling out progression to AD-type dementia than demonstrating progression.

The predictive value of the CSF biomarkers increases with longer-duration follow-up and declines with age.

The added value of CSF biomarkers is not yet clear in MCI patients in whom extensive clinical, neuropsychological examination or imaging have already been performed.